Hans Bendz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hans Bendz has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
B. Rippe
1 shared publicationC.L. Olsson
Department of Psychiatry, Malmö University Hospital, Malmö, Sweden
1 shared publicationMattias Aurell
Department of Nephrology, University of Göteborg, Göteborg, Sweden
1 shared publicationPer-Ola Attman
Department of Nephrology, University of Göteborg, Göteborg, Sweden
1 shared publicationStaffan Schön
Department of Internal Medicine, Ryhov County Hospital, Jönköping, Sweden
1 shared publication
Latest Publications
- 1 August 2010
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 74 (08) , 132-140
A comparison of plasma cystatin C and plasma creatinine for the screening of renal function in lithium-treated patients
Renal insufficiency is a serious complication of lithium treatment. Therefore, regular monitoring of plasma (P) creatinine is always part of lithium treatment safety routines. Recently P-cystatin C-estimated glomerular filtration rate (cystatin C-eGFR) had been launched as a preferable alternative to P-creatinine. To find out which of the two alternatives to prefer in the safety routines for lithium-treated patients. All 201 patients on lithium treatment at the Department of Psychiatry in Lund, Sweden. During 14 months P-cystatin C was included in the safety routines besides routine P-creatinine every 4 months. At the end of the study period, 182 patients were eligible for analysis. With iohexol clearance as reference for GFR (performed in 111/182 patients) we calculated positive and negative predictive values (PPV, NPV) for P-creatinine and for creatinine-eGFR and cystatin C-eGFR, obtained by prediction equations. We also calculated the agreement between the measures of GFR (including repeatability). PPV for cystatin C-eGFR (65%) was better than for creatinine-eGFR (48%). Combining the two resulted in a PPV of 56% and marginally increased NPV to 95%. The average of cystatin C-eGFR and creatinine-eGFR yielded PPV 67% and NPV 92%. The agreement between creatinine-eGFR and GFR was better than the agreement between cystatin C-eGFR and GFR, but both were clinically unacceptable. The repeatability of P-creatinine was acceptable for psychiatric purposes. The repeatability of cystatin C-eGFR was inferior to that of P-creatinine. Our results do not justify replacing P-creatinine by cystatin C-eGFR in the lithium treatment safety routines.
- 1 August 2010
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 74 (08) , 132-140
A comparison of plasma cystatin C and plasma creatinine for the screening of renal function in lithium-treated patients
Renal insufficiency is a serious complication of lithium treatment. Therefore, regular monitoring of plasma (P) creatinine is always part of lithium treatment safety routines. Recently P-cystatin C-estimated glomerular filtration rate (cystatin C-eGFR) had been launched as a preferable alternative to P-creatinine. To find out which of the two alternatives to prefer in the safety routines for lithium-treated patients. All 201 patients on lithium treatment at the Department of Psychiatry in Lund, Sweden. During 14 months P-cystatin C was included in the safety routines besides routine P-creatinine every 4 months. At the end of the study period, 182 patients were eligible for analysis. With iohexol clearance as reference for GFR (performed in 111/182 patients) we calculated positive and negative predictive values (PPV, NPV) for P-creatinine and for creatinine-eGFR and cystatin C-eGFR, obtained by prediction equations. We also calculated the agreement between the measures of GFR (including repeatability). PPV for cystatin C-eGFR (65%) was better than for creatinine-eGFR (48%). Combining the two resulted in a PPV of 56% and marginally increased NPV to 95%. The average of cystatin C-eGFR and creatinine-eGFR yielded PPV 67% and NPV 92%. The agreement between creatinine-eGFR and GFR was better than the agreement between cystatin C-eGFR and GFR, but both were clinically unacceptable. The repeatability of P-creatinine was acceptable for psychiatric purposes. The repeatability of cystatin C-eGFR was inferior to that of P-creatinine. Our results do not justify replacing P-creatinine by cystatin C-eGFR in the lithium treatment safety routines.
- 1 February 2010
- Published by Elsevier in Kidney International
- Vol. 77 (3) , 219-224
Renal failure occurs in chronic lithium treatment but is uncommon
- 1 February 2010
- Published by Elsevier in Kidney International
- Vol. 77 (3) , 219-224
Renal failure occurs in chronic lithium treatment but is uncommon